Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 1 Vote(s) - 5 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Antibody against clotting factor prevents thrombosis without increasing bleeding risk
#1
Wink 
A recent publication in Science Translational Medicine describes the use of a humanized monoclonal antibody against activated

FXIIa, identified using phage display, to prevent the formation of blood clots without increasing the risk of bleeding. Preventing

thrombus formation while using a bypass system often leads to unwanted bleeding, sometimes in the brain, making this breakthrough

treatment an attractive alternative to heparin.

GenScript offers Custom mAb production services to develop your specific antibody and Antibody Library and Phage Display services

which can build a library with up to 1010 individual clones.
Like Post Reply
#2
Well, all these drugs also entail an increased risk of bleeding in patients that partially offsets their beneficial effects.
Like Post Reply
  

Possibly Related Threads…
Thread
Author
  /  
Last Post



Users browsing this thread:
1 Guest(s)

Antibody against clotting factor prevents thrombosis without increasing bleeding risk51